Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc. is trading at $107.27, down 0.51% on the session. The 50 day average sits at $93.76 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 56.1, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $92.71 with resistance near $105.05, so that band frames the current range. Average daily movement is roughly $5.93, or about 5.5% of the share price, which is what any stop placement has to allow for. The overall health score of 61 out of 100 combines a trend score of 75, momentum of 60 and a risk score of 38.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.